The University of Bristol has developed a reconfigurable quantum network architecture using a quantum reconfigurable optical add-drop multiplexer (q-ROADM). This system enables dynamic, multi-user entanglement distribution over metropolitan fibre, supporting flexible topologies and multiple quantum protocols for scalable, service-oriented quantum networking.
The University of Bristol has developed a metropolitan-scale quantum communication network that enables dynamic, multi-user, and multi-protocol entanglement distribution. At the heart of this system is a quantum reconfigurable optical add-drop multiplexer (q-ROADM), which allows for the flexible and programmable allocation of entanglement resources across a network. This architecture supports various network topologies, including full-mesh, partial-mesh, and sliced sub-networks, enabling the system to adapt to changing user demands, link conditions, and specific service requirements over existing telecommunications fibre-optic infrastructure.
The system utilizes a q-ROADM that integrates wavelength multiplexing, optical switching, and polarization control to distribute polarization-entangled photon pairs from a broadband source. Key features include:
The technology is at TRL 4, representing lab and field-environment validation. The University of Bristol has successfully demonstrated this architecture in a metropolitan-scale testbed, including stable multi-user operation over deployed fibre infrastructure and the execution of complex quantum protocols. It remains a research-based demonstration of a novel quantum networking architecture.
The University of Bristol is a comprehensive Russell Group research university with a strong record of collaborating with industry on translational R&D. Its new Temple Quarter Enterprise Campus provides shared labs, demonstrator environments, and a single front door for companies through Bristol Innovations. SETsquared Bristol—based at the Engine Shed—accelerates venture creation and connects corporates to a pipeline of startups and spin‑outs. Healthcare collaboration is embedded through strategic partnerships with regional NHS trusts, including the NIHR Bristol Biomedical Research Centre, enabling clinical translation at scale. Research is supported by competitive funding from UKRI councils and the National Institute for Health and Care Research, alongside industry partnerships.